We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in our Benign Hematology. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

story of the week

Journal Scan / Research · January 04, 2023

Zanubrutinib or Ibrutinib for Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

The New England Journal of Medicine


Additional Info

The New England Journal of Medicine
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
N. Engl. J. Med 2022 Dec 13;[EPub Ahead of Print], JR Brown, B Eichhorst, P Hillmen, W Jurczak, M Kaźmierczak, N Lamanna, SM O'Brien, CS Tam, L Qiu, K Zhou, M Simkovic, J Mayer, A Gillespie-Twardy, A Ferrajoli, PS Ganly, R Weinkove, S Grosicki, A Mital, T Robak, A Osterborg, HA Yimer, T Salmi, MD Wang, L Fu, J Li, K Wu, A Cohen, M Shadman

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading